The UK and US have reached a significant trade agreement that will preserve no duties on British drug shipments entering the American market.
The Terms of the Deal
Under the terms of the agreement, the UK has committed to boost expenditure on drugs through the NHS. This pledge ensures that import taxes on these vital products will remain at zero for a duration of three years.
This deal follows recent statements to significantly raise duties on patented pharmaceutical products, with increases floated as high as double the cost.
"This deal between the UK strengthens the worldwide climate for cutting-edge drugs and establishes much-needed balance to American-British medicine commerce," a statement declared.
Trade Impact
Drugs constitute one of the Britain's biggest export categories to the United States, which is easily the largest market for leading UK drugmakers.
Trade data indicate that in the 12 months to the end of September, the UK shipped medicines valued at over eleven billion pounds to the US. This amount made up a significant portion of total UK exports in that period.
"This agreement secures employment, boosts capital expenditure and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The deal includes several key commitments from the British government:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to increase total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be capped at fifteen percent. Previously, rebates exceeded twenty percent.
Broader Context
The deal follows a long-running row between the pharmaceutical industry and the UK government over medicine costs and NHS adoption.
This friction were intensified by arguments that US customers were paying significantly more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been announced toward projects in the United States.
The Science Minister publicly accepted that the NHS needed to spend more on drugs, noting that its spending on drugs had declined as a percentage of its overall budget over the previous ten-year period.
